• Minicabecera4


Histocell Factory Opening

Histocell has inaugurated its new production centre in Larrabetzu, dedicated to the manufacture of medical devices for regenerative medicine. The plant, which required an investment of 1.6 million euros and will initially generate 10 jobs and 30 additional jobs in the coming years, demonstrates the company's commitment to maintaining both its research and manufacturing activities in the Basque Country.


Histocell SPINE

Histocell and the pharmaceutical company Ferrer today announced that the first patients have been recruited for a Phase 1/2 clinical trial of FAB117-HC, a new cell therapy medicinal product for the treatment of acute spinal cord injuries of traumatic origin.

It is the first cellular medication designed to treat acute traumatic spinal cord injury, in the first 2-3 days after the accident, that has reached the clinical regulatory phase.

SPINE (Spinal acute Injury Neurosave Evaluation) is a Phase 1/2 clinical trial that evaluates the safety and preliminary efficacy of the drug in a total of 46 adult patients with acute traumatic spinal cord injury.



In order to promote Reoxcare, innovative product for wound healing, Histocell attended last February in Madrid, the 7th Congress organized by SEHER, Spanish Society of Wounds.

At our stand, we had the opportunity to welcome all those interested in knowing the advantages of using our novel dressing for wound healing and to show success cases of patients with chronic wounds that improved satisfactorily thanks to the antioxidant properties of Reoxcare®.



The use of an antioxidant dressing on hard-to-heal wounds: a multicentre, prospective case series

Read the complete article at:


or get in touch with us for more information.